These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12935985)

  • 21. [Thalidomide for the treatment of refractory multiple myeloma].
    Kakimoto T; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
    [No Abstract]   [Full Text] [Related]  

  • 22. Thalidomide for the treatment of leptomeningeal multiple myeloma.
    Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
    Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
    [No Abstract]   [Full Text] [Related]  

  • 23. Encephalopathy in a patient after long-term treatment with thalidomide.
    Sohlbach K; Heinze S; Shiratori K; Sure U; Pagenstecher A; Neubauer A
    J Clin Oncol; 2006 Oct; 24(30):4942-4. PubMed ID: 17050881
    [No Abstract]   [Full Text] [Related]  

  • 24. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
    Ribatti D; Vacca A
    Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
    [No Abstract]   [Full Text] [Related]  

  • 25. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thalidomide in multiple myeloma.
    Kishi Y; Oki Y; Machida U
    N Engl J Med; 2000 Mar; 342(13):975; author reply 975-6. PubMed ID: 10744492
    [No Abstract]   [Full Text] [Related]  

  • 28. [Thalidomide: (re)discovery of a not very dear old molecule].
    Bressoud A; Schwab BZ
    Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide--a treatment for cancer?
    Mayo Clin Health Lett; 2000 Jun; 18(6):4. PubMed ID: 10868128
    [No Abstract]   [Full Text] [Related]  

  • 30. [Thalidomide and others: new treatment for myeloma].
    Malphettes M; Fermand JP
    Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
    [No Abstract]   [Full Text] [Related]  

  • 31. Thalidomide.
    Waldman AR
    Clin J Oncol Nurs; 2000; 4(2):99-100. PubMed ID: 11107384
    [No Abstract]   [Full Text] [Related]  

  • 32. Thalidomide shows promise as cancer treatment.
    Health News; 2000 Jan; 6(1):8. PubMed ID: 11019665
    [No Abstract]   [Full Text] [Related]  

  • 33. Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
    Ribatti D; Vacca A
    Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476
    [No Abstract]   [Full Text] [Related]  

  • 34. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
    Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
    Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 38. Thalidomide: from teratogen to anti-angiogenic.
    Grover JK; Vats K
    Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
    Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
    Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.